Sunday, November 22, 2026

Lupin gets Establishment Inspection Report from the USFDA for its Goa facility

Date:

Lupin Ltd. on Friday, February 27, said it has received an establishment inspection report (EIR) from the US Food and Drug Administration (USFDA) for its Goa facility with a satisfactory voluntary action indicated (VAI) classification.The US drug regulator had inspected the facility from November 10, 2025 till November 21.

“The outcome reflects our continued focus on quality excellence and regulatory compliance, reinforcing our commitment to delivering safe and effective medicines to patients worldwide,” Nilesh Gupta, the managing director of Lupin, said.
On another note, the pharma major on Wednesday said the GST department of Maharashtra had initiated an inspection and search at its office. It said it was cooperating with authorities and the proceedings had no impact on its financials, operations and other activities.Earlier this week, Lupin received the USFDA’s approval for its abbreviated new drug application (ANDA) for Brivaracetam oral solution in the 10mg/ml strength. It is indicated for the treatment of partial-onset seizures in patients aged one month and older.

Lupin shares were up 0.2% at ₹2,328.7 apiece around 1.55 pm. The stock has gained 22.5% in the last six months.

Also Read: Sarda Energy shares gain 8% after SC dismisses plea of unsuccessful bidders for SKS Power acquisition

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Share post:

Subscribe

spot_imgspot_img

Popular

More like this
Related

CLSA sees better US-India trade outlook; expects Fed and RBI to raise rates in December

The US is likely to push ahead with trade...

‘Trump has cost us’: After midterm losses, MAGA asks if it’s over

As Republicans faced a nationwide drubbing in Tuesday’s midterm...

Prashant Jain sees 12-15% annual returns from Indian equities over 3-5 years

Question We've had a very painful period for the equity...

Raamdeo Agrawal sees FIIs return as earnings improve and valuations turn attractive

Question Looking at the valuation compression across the market, are...